Neurotechnology – technologies that interact with, monitor, or augment the human nervous system – is transitioning from research laboratories to clinical and consumer applications. EEG monitoring platforms, brain-computer interface companies, neuromodulation device makers, and neurofeedback application developers are all evaluating new market entry opportunities as clinical validation accumulates and regulatory pathways mature. GreyRadius helps neurotechnology businesses validate clinical and enterprise demand, navigate regulatory requirements, execute GTM plans, and raise capital.
Why now? Regulatory approval for neurotechnology devices is accelerating – FDA, CE, and Asian regulatory bodies are establishing clearer pathways for digital neurology, neuromodulation, and brain-computer interface products. Clinical applications in epilepsy monitoring, stroke rehabilitation, and mental health treatment are achieving commercial launch in multiple markets. The companies establishing clinical reference deployments in 2025–2028 will define the neurotech commercial ecosystem.
Global neurotechnology market is projected to reach $22B by 2030 – growing at 13% annually as clinical neurology monitoring, neuromodulation, and consumer neurofeedback all achieve commercial deployment.
Stroke rehabilitation neurotechnology is the largest near-term clinical application – brain-computer interfaces and EEG-guided rehabilitation platforms are demonstrating clinical efficacy that is driving hospital procurement.
Mental health neuromodulation is growing rapidly – transcranial magnetic stimulation and transcranial direct current stimulation devices are achieving clinical approval for depression treatment in multiple markets.
Consumer neurofeedback is growing in sports performance and wellness – professional sports teams, corporate wellness programmes, and premium consumer health apps are all adopting EEG-based cognitive performance tools.
If you recognise your situation below, we can help.
Clinical demand and hospital system validation
You need to validate that neurologists and hospital systems in your target market are willing to adopt and integrate your neurotechnology into clinical practice.
Regulatory classification and approval pathway
You need to understand how your neurotechnology is classified and what clinical evidence and regulatory approval processes apply in your target market.
Clinical partner and KOL identification
You need to identify neurology departments, rehabilitation centres, and key opinion leader neurologists as clinical validation and early adoption partners.
GTM for a neurotechnology company
You have a neuromonitoring device, BCI system, or neurofeedback platform and need a go-to-market strategy.
Raising capital for a neurotechnology venture
You are raising investment and need a pitch book grounded in clinical validation data and market sizing.
Enterprise and consumer channel strategy
You need a strategy for reaching corporate wellness buyers and sports performance teams as non-clinical channels for consumer neurotechnology.
Every engagement is grounded in primary research and delivers a measurable outcome.
Validate clinical and enterprise demand for neurotechnology in a new market. Covers neurologist and hospital administrator interviews, regulatory pathway mapping, competitive analysis, and a Go/Defer/Kill recommendation.
Learn more →Full financial and operational feasibility for neurotechnology investments. Covers clinical adoption modelling, regulatory pathway cost, reimbursement timeline, and investor-ready projections.
Learn more →End-to-end market entry for neurotechnology companies. Regulatory approval pathway, clinical KOL identification, hospital ICP, and first-clinical-deployment milestone.
Learn more →Embedded GTM team for neurotech platforms. Hospital outreach, KOL engagement, and enterprise wellness pipeline management.
Learn more →Investor-ready pitch books for neurotechnology ventures. Clinical-evidence-validated market sizing, regulatory narrative, and investor identification across medtech and deep tech investors.
Learn more →AI use-case prioritisation in neurotechnology – from neural signal processing and seizure detection to personalised neuromodulation protocol optimisation and cognitive performance prediction.
Learn more →80% of our insight comes from first-party interviews with buyers, competitors, and regulators – not secondary data that everyone else has.
Our AI layer compresses research timelines by 60% and surfaces pattern-matching from 200+ prior mandates – so you get faster, deeper answers.
We measure success by first contracts signed, capital raised, and markets entered – not deliverables produced. Every mandate has a milestone.
200+
Projects delivered
100+
SaaS & tech clients
80%
Primary research-led
4
Countries / offices
Healthcare · Market Entry
Healthcare · GTM Execution
Healthcare · Assessment
Both. We work with implantable device companies on regulatory pathway and clinical market entry, and with non-invasive neurotech companies on clinical and enterprise GTM and fundraising.
Gulf, Southeast Asia, South Asia, and Europe – markets with active neurology infrastructure investment and growing clinical neurotechnology procurement.
Typically 8–12 weeks given the complexity of regulatory pathway mapping and clinical stakeholder research.
Yes. KOL identification and initial clinical discussions are part of our market entry execution service.
GreyRadius research notes, market entry signals, and sector briefs – delivered weekly. No fluff.
Not sure which engagement fits? Take our free 2-minute diagnostic →
Primary research. AI-enabled analysis, expert-reviewed. Outcomes-based delivery – across Gulf, Southeast Asia, South Asia, Europe.
